ArticleBMC public health2026
Bayesian model prediction of colorectal cancer incidence in Jiangsu Province, China, a cancer registry-based study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe most recent colorectal cancer incidence trends in Jiangsu Province, China, have not been reported; this study aims to provide a comprehensive analysis of present local incidence patterns and future trends projected through 2035.
methodsAnnual data on colorectal cancer cases from 16 cancer registries in Jiangsu Province were analyzed to assess temporal trends from 2009 to 2021. Trends in previous incidence rates of colorectal cancer were analyzed using the Joinpoint regression model, and future incidence rates from 2022 to 2035 were projected using the Bayesian age-period-cohort model.
resultsBoth crude and age-standardized incidence rates of colorectal cancer presented significant upward trends from 2009 to 2021, with average annual percentage changes of 6.16% (95% CI: 5.72–6.63%) and 3.55% (95% CI: 2.86–4.25%), respectively; these rates were highest in urban males and increased fastest in rural males. APC model analysis revealed a pronounced age effect and modest cohort effect for incidence growth. By 2035, overall crude and age-standardized incidence rates were projected to reach 87.69 per 100,000 and 29.20 per 100,000, respectively, with males contributing most significantly to the overall increase.
conclusionsWithout enhanced interventions, the crude incidence rate of CRC in 2035 is projected to reach 2.25 times the 2021 baseline. Screening strategies involving fecal immunochemical test and colonoscopy should be prioritized to reduce population-level incidence rates, particularly among males and those older than 50.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.